Board Meeting4 Nov 2026, 11:11 pm

Tavexia Lifecare Board Approves Financial Results and Fund Raising Proposal

AI Summary

Tavexia Lifecare Ltd's Board of Directors convened on November 4, 2026, approving the Un-Audited Financial Results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report. The board also approved a proposal for raising funds up to ₹68 Crore (Rupees Sixty-Eight Crores Only) through various modes, including preferential issue or rights issue, to finance the proposed acquisition of 60% equity in Meyonex Pharmaceuticals Limited. Additionally, the company announced a change in its Registrar & Transfer Agent from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd.

Key Highlights

Board approved Q2 FY27 Un-Audited Financial Results and Limited Review Report.
Proposal to raise up to ₹68 Crore for Meyonex Pharmaceuticals acquisition approved.
Company to change Registrar & Transfer Agent to Skyline Financial Services.
Statement of deviation on use of proceeds from Right Issue considered.

View BSE Filing

SATTVASUKU

Distributors

Mayukh Dealtrade Ltd

Price Impact